1297609-87-0

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1-bromo-1-[3,5-bis(trifluoromethyl)phenyl]ethane is used as a pharmaceutical intermediate for the development of new drugs. Its unique structure, including the trifluoromethyl group and bromine atom, makes it a valuable building block in the synthesis of bioactive molecules with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic chemistry, (S)-1-bromo-1-[3,5-bis(trifluoromethyl)phenyl]ethane serves as a key precursor for the synthesis of complex organic molecules. The presence of the bromine atom allows for various coupling reactions, while the trifluoromethyl group can be used to introduce specific properties to the final product, making it a versatile compound for creating a wide range of organic compounds.
Used in Chemical Research:
(S)-1-bromo-1-[3,5-bis(trifluoromethyl)phenyl]ethane is also utilized in chemical research to study the effects of different functional groups on the properties and reactivity of molecules. Its chiral nature allows researchers to explore the impact of stereochemistry on the biological activity and pharmacokinetics of synthesized compounds, contributing to the advancement of chemical knowledge and the development of more effective drugs.

Upstream product

• 160376-84-1 1-[3,5-bis(trifluoromethyl)phenyl]ethyl bromide 
• 225920-05-8 (S)-3,5-bis(trifluoromethyl)-1-phenylethanol 
• 368-63-8 (R)-[3,5-bis(trifluoromethyl)phenyl]ethanol 

Downstream Products

• 552292-08-7 Rolapitant 

Relevant academic research and scientific papers

AGENT FOR INHIBITING EXPRESSION OF NPC1L1 AND/OR LIPG MRNA AND AGENT FOR PREVENTING AND/OR TREATING OBESITY

Provided is an agent for treating and/or preventing obesity. An agent for suppressing expression of NPC1L1 (Niemann-Pick disease, type C1, gene-like 1) and/or LIPG (Lipase, endothelial) mRNA, and an agent for preventing and/or treating obesity, each comprising, as an active ingredient, a compound having CETP inhibitory activity, or a salt thereof, or a solvate thereof.

AGENT FOR INHIBITING EXPRESSION OF LIPID METABOLISM RELATED MRNA

The present invention is intended to provide a pharmaceutical product for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the present invention is also intended to provide a preventive and/or therapeutic agent for various diseases based on inhibition of expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and the present invention relates to an agent for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and relates also to a preventive and/or therapeutic agent for various diseases based on the inhibition of the expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the agent comprising a compound represented by Formula (I), its salt, or a solvate of any of them as an active ingredient: wherein the symbols are the same as those given in the description..

METHOD FOR PRODUCING OPTICALLY ACTIVE 1-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANE

A method for preparing optically active 1-bromo-1-[3,5-bis(trifluoromethyl)phenyl]ethane having a high optical purity, which comprises the step of brominating optically active 1-[3,5-bis(trifluoromethyl)phenyl]ethanol by using, as a brominating agent, (a) a combination of a phosphorus halide and hydrogen bromide, (b) a combination of 1,2-dibromo-1,1,2,2-tetrachloroethane and an organic phosphorous compound represented by the general formula (I): P(R1)(R2)(R3) (in the formula, R1, R2, and R3 independently represent a C6-10 aryl group, a C6-10 aryloxy group, a C1-10 alkyl group, a C1-10 alkoxyl group, a C3-6 cycloalkyl group, or a C3-6 cycloalkoxy group), or (c) a combination ofN-bromosuccinimide and a dialkyl sulfide.